Mast cell leukemia

Blood

Volumn 121, Issue 8, 2013, Pages 1285-1295

  Georgin Lavialle, Sophie ^a,b,c   Lhermitte, Ludovic ^b,d   Dubreuil, Patrice ^a,e,f   Chandesris, Marie Olivia ^a,g   Hermine, Olivier ^a,b,d,g   Damaj, Gandhi ^a,d,h  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL TENON   (France)

^d CNRS   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD2 ANTIGEN; CLADRIBINE; CORTICOSTEROID; CYTARABINE; DASATINIB; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MASITINIB; MIDOSTAURIN; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; TET2 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW EXAMINATION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL NUCLEUS; CELL STRUCTURE; CHILDHOOD LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DIARRHEA; DRUG ERUPTION; DRUG MEGADOSE; EDEMA; EOSINOPHILIC LEUKEMIA; EXON; GENE SEQUENCE; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SARCOMA; SURVIVAL TIME; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE; VOMITING;

EID: 84874445066     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-442400     Document Type: Review

References (95)

1. Swerdlow SH CE, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
2. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435-453. (Pubitemid 46817344)
3. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122(5):695-717. (Pubitemid 37100296)
4. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol. 2004;11(1):58-64. (Pubitemid 38021722)
5. Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep. 2004;3(3):197-202.
6. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-5736.
7. Valentini CG, Rondoni M, Pogliani EM, et al. Mast cell leukemia: a report of ten cases. Ann Hematol. 2008;87(6):505-508.
8. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia. 2012;26(5):951-958.
9. Noack F, Sotlar K, Notter M, Thiel E, Valent P, Horny HP. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. Leuk Lymphoma. 2004;45(11):2295-2302. (Pubitemid 39504325)
10. Joachim G. Uber Mastzellenleukamien. Deutsches Archives fur Klinische Medizin. 1906;87:437.
11. Baghestanian M, Bankl H, Sillaber C, et al. A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone. Leukemia. 1996;10(1):159-166. (Pubitemid 26052995)
12. Coser P, Quaglino D, De Pasquale A, Colombetti V, Prinoth O. Cytobiological and clinical aspects of tissue mast cell leukaemia. Br J Haematol. 1980;45(1):5-12. (Pubitemid 10094382)
13. Dalton R, Chan L, Batten E, Eridani S. Mast cell leukaemia: evidence for bone marrow origin of the pathological clone. Br J Haematol. 1986;64(2):397-406. (Pubitemid 16007307)
14. Daniel MT, Flandrin G, Bernard J. [Acute mastcell leukemia. Cytochemical and ultrastructural study, about a particular case (author's transl)]. Nouv Rev Fr Hematol. 1975;15(3):319-332.
15. Efrati P, Klajman A, Spitz H. Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations. Blood. 1957;12(10):869-882.
16. Friedman BI, Will JJ, Freiman DG, Braunstein H. Tissue mast cell leukemia. Blood. 1958;13(1):70-78.
17. Kyriakou D, Kouroumalis E, Konsolas J, et al. Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis-report of four cases. Am J Gastroenterol. 1998;93(1):106-108. (Pubitemid 29065525)
18. Le Cam MT, Wolkenstein P, Cosnes A, et al. [Acute mast cell leukemia disclosed by vasomotor flushing]. Ann Dermatol Venereol. 1997;124(9):621-622. (Pubitemid 27428262)
19. Szweda J A AJ, Fine G, Nixon RK, Rupe CE. Systemic mast cell disease: a review and report of three cases. Am J Med. 1962;32(2):227-239.
20. Travis WD, Li CY, Hoagland HC, Travis LB, Banks PM. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc. 1986;61(12):957-966. (Pubitemid 17205206)
21. Cherner JA, Jensen RT, Dubois A, O'Dorisio TM, Gardner JD, Metcalfe DD. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology. 1988;95(3):657-667.
22. Friedman BS, Steinberg SC, Meggs WJ, Kaliner MA, Frieri M, Metcalfe DD. Analysis of plasma histamine levels in patients with mast cell disorders. Am J Med. 1989;87(6):649-654. (Pubitemid 20006503)
23. Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis: a disease of the hematopoietic stem cell. Dtsch Arztebl Int. 2008;105(40):686-692.
24. Arredondo AR, Gotlib J, Shier L, et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010;85(8):600-606.
25. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74(2):121-132. (Pubitemid 46985284)
26. Valent P. Mast cell leukemia-a rare form of myeloid leukemia. Wien Klin Wochenschr. 2002;114(5-6):173-174. (Pubitemid 34298145)
27. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010;125(3):719-726.
28. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366-2372. (Pubitemid 44497521)
29. Georgin-Lavialle S, Lhermitte L, Suarez F, et al. Mast cell leukemia: identification of a new c-Kit mutation, dup (501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol. 2012;89(1):47-552.
30. Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol. 2011;86(6):531-535.
31. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103(8):3222-3225. (Pubitemid 38451702)
32. Georgin-Lavialle S, Aguilar C, Guieze R, et al. Mast cell sarcoma, a rare and aggressive entity: report of 2 cases and review of the literature [published online ahead of print November 5, 2012]. J Clin Oncol. doi: JCO.2012.41.9549.
33. Spector MS, Iossifov I, Kritharis A, et al. Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor beta chain and KIT V654A. Leukemia. 2012;26(6):1422-1425.
34. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23(5):900-904.
35. Soucie E HK, Hanssens K, Mercher T, et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood. 2012;120(24):4846-4849.
36. Chantorn R, Shwayder T. Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. Pediatr Dermatol. 2012;29(5):605-609.
37. Waters WJ, Lacson PS. Mast cell leukemia presenting as urticaria pigmentosa; report of a case. Pediatrics. 1957;19(6):1033-1042.
38. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D (816) V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804-815.
39. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010;116(26):5812-5817.
40. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med. 1992;326(9):619-623.
41. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998;138(3):489-495. (Pubitemid 28145521)
42. Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma. 1996;22(5-6):501-508. (Pubitemid 26341017)
43. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119(4):1090-1097. (Pubitemid 35463838)
44. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28(3):249-257. (Pubitemid 37550059)
45. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol. 1991;85(4):220.
46. Penack O, Sotlar K, Noack F, Horny HP, Thiel E, Notter M. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol. 2005;84(10):692-693. (Pubitemid 41554248)
47. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34 (+), c-kit (+), and expresses aminopeptidase N (CD13). Blood. 1999;94(7):2333-2342. (Pubitemid 29467681)
48. Carrera CJ, Terai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990;86(5):1480-1488. (Pubitemid 20372594)
49. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004;28(2):127-131. (Pubitemid 37492938)
50. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270-4276. (Pubitemid 37494083)
51. Aichberger KJ, Gleixner KV, Mirkina I, et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood. 2009;114(26):5342-5351.
52. Gabillot-Carre M, Lepelletier Y, Humbert M, et al. Rapamycin inhibits growth and survival of D816Vmutated c-kit mast cells. Blood. 2006;108(3):1065-1072. (Pubitemid 44154646)
53. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107(2):752-759. (Pubitemid 43076402)
54. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92(4):1736-1744. (Pubitemid 23304537)
55. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999;96(4):1609-1614. (Pubitemid 29098499)
56. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12(3):312-314. (Pubitemid 26080092)
57. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741-1744. (Pubitemid 34533049)
58. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest. 2007;87(4):365-371. (Pubitemid 46474567)
59. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25(7):571-576. (Pubitemid 32506764)
60. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 2003;22(5):660-664. (Pubitemid 36269279)
61. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1(12):1115-1124.
62. Lahortiga I, Akin C, Cools J, et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica. 2008;93(1):49-56. (Pubitemid 351156151)
63. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;107(2):345-351. (Pubitemid 44036564)
64. Piccaluga PP, Rondoni M, Paolini S, Rosti G, Martinelli G, Baccarani M. Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther. 2007;7(10):1597-1611. (Pubitemid 47597145)
65. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362(9383):535-536.
66. Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010;85(12):921-925.
67. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291. (Pubitemid 43990640)
68. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473-481. (Pubitemid 43166056)
69. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosomenegative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12):3906-3915.
70. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol. 2008;80(5):456-458. (Pubitemid 351503111)
71. Kneidinger M, Schmidt U, Rix U, et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008;111(6):3097-3107.
72. Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008;38(11):869-873.
73. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865-2870. (Pubitemid 41510766)
74. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106(2):721-724. (Pubitemid 40981272)
75. Gotlib J, Kluin-Nelemans HC, George TI, et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood. 2012;120(21):Abstract 799.
76. Samorapoompichit P, Steiner M, Lucas T, et al. Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. Leuk Lymphoma. 2003;44(3):509-515. (Pubitemid 36113897)
77. Brcic L, Vuletic LB, Stepan J, et al. Mast-cell sarcoma of the tibia. J Clin Pathol. 2007;60(4):424-425. (Pubitemid 46596565)
78. Yoshida C, Takeuchi M, Tsuchiyama J, Sadahira Y. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. Intern Med. 2009;48(22):1973-1978.
79. Lin JT, Lachmann E, Nagler W. Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report. Arch Phys Med Rehabil. 2002;83(6):860-863. (Pubitemid 34721489)
80. Spyridonidis A, Thomas AK, Bertz H, et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34(6):515-519. (Pubitemid 39264042)
81. Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant. 2006;37(4):353-358. (Pubitemid 43250468)
82. Chen TY, Chen JS, Huang WT, Su WC, Tsao CJ. Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32(1):111-114.
83. Hissard R, Moncourier L, Jacquet J. Examination of a new hematodermia; mastocytosis. Presse Med. 1951;59(82):1765-1767.
84. Brinkmann E. Mast cell reticulosis (tissular basophiloma) with histamine flushes and development into tissular basophilic leukemia. Schweiz Med Wochenschr. 1959;89:1046-1048.
85. Mutter RD, Tannenbaum M, Ultmann JE. Systemic mast cell disease. Ann Intern Med. 1963;59:887-906.
86. Clancy RL, Gauldie J, Vallieres M, Bienenstock J, Day RP, Pineo GF. An approach to immunotherapy using antibody to IgE in mast cell leukemia. Cancer. 1976;37(2):693-696.
87. Kimura A, Tanaka R, Taketomi Y, et al. [A case of mastocytoma with leukemic manifestation of its immature form in the terminal stage (author's transl)]. Rinsho Ketsueki. 1979;20(9):1137-1146.
88. Horny HP, Parwaresch MR, Kaiserling E, et al. Mast cell sarcoma of the larynx. J Clin Pathol. 1986;39(6):596-602. (Pubitemid 16069663)
89. Escribano L, Orfao A, Villarrubia J, et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry. 1997;30(2):98-102. (Pubitemid 27240014)
90. Pauls JD, Brems J, Pockros PJ, et al. Mastocytosis: diverse presentations and outcomes. Arch Intern Med. 1999;159(4):401-405. (Pubitemid 29091630)
91. Horny HP, Krokowski M, Feller AC, Hintze G, Sotlar K, Valent P. [Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]. Wien Klin Wochenschr. 2002;114(5-6):222-228. (Pubitemid 34298152)
92. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419-432. (Pubitemid 38316735)
93. Krauth MT, Fodinger M, Rebuzzi L, Greul R, Chott A, Valent P. Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens. Haematologica. 2007;92(12):e126-e129.
94. Yoshida M, Nishikawa Y, Yamamoto Y, et al. Mast cell leukemia with rapidly progressing portal hypertension. Pathol Int. 2009;59(11):817-822.
95. Joris M, Georgin-Lavialle S, Chandesris MO, et al. Mast cell leukaemia: c-KIT mutations are not always positive. Case Report Hematol; 2012:517546.